Suppr超能文献

全球检测与口服抗凝治疗的管理

Global assays and the management of oral anticoagulation.

作者信息

Brinkman Herm Jan M

机构信息

Department of Plasma Proteins, Sanquin Research, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands.

出版信息

Thromb J. 2015 Feb 10;13:9. doi: 10.1186/s12959-015-0037-1. eCollection 2015.

Abstract

Coagulation tests range from global or overall tests to assays specific to individual clotting factors and their inhibitors. Whether a particular test is influenced by an oral anticoagulant depends on the principle of the test and the type of oral anticoagulant. Knowledge on coagulation tests applicable in monitoring status and reversal of oral anticoagulation is a prerequisite when studying potential reversal agents or when managing anticoagulation in a clinical setting. Specialty tests based on the measurement of residual activated factor X (Xa) or thrombin activity, e.g., are highly effective for determining the concentration of the new generation direct factor Xa- and thrombin inhibitors, but these tests are unsuitable for the assessment of anticoagulation reversal by non-specific prohemostatic agents like prothrombin complex concentrate (PCC) and recombinant factor VIIa (FVIIa). Global coagulation assays, in this respect, seem more appropriate. This review evaluates the current status on the applicability of the global coagulation assays PT, APTT, thrombin generation and thromboelastography in the management of oral anticoagulation by vitamin K antagonists and the direct factor Xa and thrombin inhibitors. Although all global tests are influenced by both types of anticoagulants, not all tests are useful for monitoring anticoagulation and reversal thereof. Many (pre)analytical conditions are of influence on the assay readout, including the oral anticoagulant itself, the concentration of assay reagents and the presence of other elements like platelets and blood cells. Assay standardization, therefore, remains an issue of importance.

摘要

凝血检测范围从整体或全面检测到针对个别凝血因子及其抑制剂的测定。特定检测是否受口服抗凝剂影响取决于检测原理和口服抗凝剂的类型。在研究潜在的逆转剂或在临床环境中管理抗凝时,了解适用于监测口服抗凝状态和逆转的凝血检测是一个先决条件。例如,基于测量残余活化因子X(Xa)或凝血酶活性的特殊检测对于确定新一代直接因子Xa和凝血酶抑制剂的浓度非常有效,但这些检测不适用于评估非特异性促止血剂(如凝血酶原复合物浓缩物(PCC)和重组因子VIIa(FVIIa))对抗凝逆转的效果。在这方面,整体凝血检测似乎更合适。本综述评估了整体凝血检测PT、APTT、凝血酶生成和血栓弹力图在维生素K拮抗剂以及直接因子Xa和凝血酶抑制剂口服抗凝管理中的适用性现状。尽管所有整体检测都受这两种抗凝剂的影响,但并非所有检测都可用于监测抗凝及其逆转。许多(前)分析条件会影响检测读数,包括口服抗凝剂本身、检测试剂的浓度以及血小板和血细胞等其他成分的存在。因此,检测标准化仍然是一个重要问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6c/4355453/e11987a701b8/12959_2015_37_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验